AbbVie (NYSE: ABBV) reported Q3 EPS of $1.41, $0.03 better than the analyst estimate of $1.38. Revenue for the quarter came in at $7 billion versus the consensus estimate of $7 billion.

GUIDANCE:

AbbVie sees FY2017 EPS of $5.53-$5.55, versus the consensus of $5.53.

Update To Long-Term Strategic and Financial Objectives

Today, AbbVie is providing an update to the company\'s long-term strategic and financial objectives, including its progress against the long-range guidance provided in October 2015. AbbVie is on track to meet or exceed its long-range guidance, and now expects global HUMIRA sales to approach $21 billion in 2020. For 2018, AbbVie expects adjusted EPS in the range of $6.37 to $6.57, reflecting growth of approximately 15 to 19 percent from the mid-point of the 2017 revised guidance range. The company\'s 2018 adjusted diluted EPS guidance excludes intangible asset amortization expense, changes in the fair value of contingent consideration, and other specified items. The company has also posted a slide presentation regarding the strategic update on the Investor Relations website at investors.abbvie.com.

For earnings history and earnings-related data on AbbVie (ABBV) click here.